# Icsm Treat Anemia With Tt

> Testosterone therapy is more effective than placebo at correcting anemia in middle-aged and older men with confirmed hypogonadism. Consider this approach when evaluating a hypogonadal man with anemia and questioning whether testosterone will improve hemoglobin or if testosterone therapy should be used for anemia.

- Skill: `dromlakhani/icsm-treat-anemia-with-tt` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/icsm-treat-anemia-with-tt`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/icsm-treat-anemia-with-tt/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/icsm-treat-anemia-with-tt

---


# Treat anemia with testosterone therapy in hypogonadal men

## STEP 1 — Gather Information
Collect morning total testosterone (fasting, 07:00–11:00) on two occasions, hemoglobin, hypogonadal symptoms (low libido, fatigue, erectile dysfunction), iron studies, vitamin B12/folate, renal/liver function, baseline hematocrit, and prostate assessment (PSA, DRE) if testosterone therapy is contemplated.

## STEP 2 — Rule In / Rule Out
Is the man hypogonadal (total testosterone <12 nmol/L on two occasions plus symptoms) AND anemic (hemoglobin <12.7 g/dL) with no identifiable non‑hypogonadal cause? If yes, proceed; if no, investigate alternative anemia etiologies or refrain from using testosterone therapy for anemia.

## STEP 3 — Classify or Stratify
Assess contraindications: hematocrit ≥54%, active prostate cancer, desire for fertility, untreated severe sleep apnea, or high thrombotic risk. If any contraindication is present, do not initiate testosterone therapy; otherwise classify the patient as a candidate for therapy.

## STEP 4 — Decide
Initiate testosterone therapy (gel, injection, or other formulation) targeting the mid‑normal total testosterone range; re‑evaluate hemoglobin and hematocrit at 3 months; expect a hemoglobin rise of ≥1 g/dL and resolution of anemia (hemoglobin ≥12.7 g/dL) in responders.

## Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone therapy in eugonadal men or solely for anemia without hypogonadism; monitor hematocrit to avoid polycythemia (>54%) and hold or reduce dose if exceeded; avoid in men seeking fertility (use gonadotropins instead); do not ignore prostate cancer screening (PSA/DRE per guidelines); anemia due to iron deficiency, B12 deficiency, or chronic disease will not respond to testosterone therapy alone.

## Concrete Clinical Example
A 62‑year‑old man presents with fatigue, low libido, and hemoglobin 11.8 g/dL. Morning total testosterone is 9.5 nmol/L (confirmed on repeat) and hematocrit is 49%. Iron studies are normal. He is started on testosterone gel 50 mg daily. At 3‑month follow‑up, hemoglobin is 13.2 g/dL and hematocrit 52%, confirming anemia resolution.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036